그라피프란트

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Hypersensitivity to grapiprant
• Concurrent use with other NSAIDs or corticosteroids
• Breeding, pregnant, or lactating dogs
• Dogs under 9 months of age or weighing less than 3.6 kg
• Dogs under 9 months of age
• Dogs weighing less than 3.6 kg
• Cats (not authorized for use)
• Known hypersensitivity to grapiprant

이상반응

• Vomiting
• Diarrhea
• Anorexia
• Lethargy
• Decreased serum albumin
• Soft-formed faeces
• Diarrhoea
• Inappetence
• Mild decreases in serum albumin and total protein
• Haematemesis (very rare)
• Haemorrhagic diarrhoea (very rare)

약물 상호작용

• Other NSAIDs · Increased risk of gastrointestinal toxicity · major
• Corticosteroids · Increased risk of gastrointestinal ulceration · major
• Highly protein-bound drugs · Potential competition for protein binding sites · moderate
• Other NSAIDs (e.g., meloxicam, carprofen) · Increased risk of gastrointestinal toxicity and adverse effects. Concurrent use should be avoided. · major
• Corticosteroids (e.g., prednisolone, dexamethasone) · Increased risk of gastrointestinal ulceration and adverse effects. Concurrent use should be avoided. · major

모니터링

• Clinical response (pain scoring)
• Fecal consistency
• Appetite
• Baseline and periodic CBC, serum biochemistry (especially albumin, BUN, creatinine, liver enzymes)
• Clinical response to pain management
• Signs of gastrointestinal upset or ulceration (vomiting, diarrhoea, melaena)
• Serum albumin and total protein levels
• Baseline and periodic renal and hepatic panels, especially in older or compromised patients

과용량

Overdoses up to 15x the recommended dose for 9 months resulted in mild, transient GI signs (vomiting, soft feces) and mild decreases in total protein and albumin. No specific antidote exists; treat symptomatically with GI protectants and supportive care.